Emergent Biosolutions vs Travere Therapeutics
Emergent Biosolutions is the larger business, with $743m of revenue in fiscal 2025 against $491m for Travere Therapeutics (1.5 times as much). Travere Therapeutics grew faster (110.5% against -28.8%). Emergent Biosolutions kept more of each dollar of sales as profit: a net margin of 7.1% against -5.2%.
| Latest fiscal year | Emergent BiosolutionsEBS, 2025 | Travere TherapeuticsTVTX, 2025 |
|---|---|---|
| Revenue | $743m | $491m |
| Revenue growth | -28.8% | 110.5% |
| Net income | $52.6m | −$25.5m |
| Operating margin | 13.5% | — |
| Net margin | 7.1% | -5.2% |
| Return on equity | 10.5% | -29.4% |
| Free cash flow | $157m | $37.8m |
| Cash | $205m | $93.0m |
| Total debt | $590m | $312m |
| Debt to equity | 112.8% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $24.9m | — |
| Employees | 900 | 497 |
| Market value | $318m | $4.63bn |
| Price vs our value range | Below our value range | — |
| Moat score | 27 (Weak) | 36 (Weak) |
| Insider trades, 12 months | 0 buys, 15 sales | 0 buys, 119 sales |